Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Belgian Volition Srl (Be/Be) is active in the Biotechnology & Pharmaceuticals technology area with 4 pending office actions. These actions are distributed among 4 distinct examiners, which indicates that no pending matters are currently being reviewed by the same individual. The portfolio's prosecution is spread across 3 distinct art units, suggesting a concentration of technical subject matter despite the variety of examiners involved.
NGUYEN, NAM P is the busiest examiner for this company, currently overseeing 1 busiest examiner pending office action. This 1 action is part of the 4 total pending office actions for the portfolio. Because there are 4 distinct examiners for 4 pending office actions, the workload is evenly split at the individual level. Practitioners should prepare for distinct prosecution styles across the 3 distinct art units involved in the current workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (25%) |
| §101 + other | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
| NGUYEN, NAM P | 1 | 54.8% | +48.7% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| DUNN, MCKENZIE A | 1 | 53.8% | +56.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256191 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | AEDER, SEAN E | 9d |
| 18260011 | TRANSCRIPTION FACTOR BINDING SITE ANALYSIS OF NUCLEOSOME DEPLETED CIRCULATING CELL FREE CHROMATIN FRAGMENTS | SCHLOOP, ALLISON ELIZABETH | — |
| 18260018 | CIRCULATING TRANSCRIPTION FACTOR ANALYSIS | NGUYEN, NAM P | — |
| 17895953 | TRIAGING METHOD USING CELL FREE NUCLEOSOME LEVELS | DUNN, MCKENZIE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256191 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | AEDER, SEAN E | 9d |
| 18260011 | TRANSCRIPTION FACTOR BINDING SITE ANALYSIS OF NUCLEOSOME DEPLETED CIRCULATING CELL FREE CHROMATIN FRAGMENTS | SCHLOOP, ALLISON ELIZABETH | — |
| 18260018 | CIRCULATING TRANSCRIPTION FACTOR ANALYSIS | NGUYEN, NAM P | — |
| 17895953 | TRIAGING METHOD USING CELL FREE NUCLEOSOME LEVELS | DUNN, MCKENZIE A | — |
| Art Unit | Apps |
|---|---|
| 1678 | 2 |
| 1682 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260011 | TRANSCRIPTION FACTOR BINDING SITE ANALYSIS OF NUCLEOSOME DEPLETED CIRCULATING CELL FREE CHROMATIN FRAGMENTS | SCHLOOP, ALLISON ELIZABETH | 1682 | §101§103§112 | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18260018 | CIRCULATING TRANSCRIPTION FACTOR ANALYSIS | NGUYEN, NAM P | 1678 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 29, 2023 |
| 18256191 | DIAGNOSTIC METHOD FOR MULTIPLE SCLEROSIS | AEDER, SEAN E | 1642 | §101§102§103§112 | Non-Final OA | 9d | Pending | Jun 06, 2023 |
| 17895953 | TRIAGING METHOD USING CELL FREE NUCLEOSOME LEVELS | DUNN, MCKENZIE A | 1678 | §101 | Non-Final OA | — | Pending | Aug 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial